Fibrosis is a common end-stage sequella of a number of acute and chronic lung diseases. Current concepts of pathogenesis implicate dysregulated interactions between epithelial cells and mesenchymal cells. Although investigative efforts have documented important roles for cytokines and growth factors in the pathogenesis of fibrotic lung diseases, these observations have not as yet been translated into efficacious therapies, and there is a pressing need for new pathogenetic insights and therapeutic approaches for these devastating disorders. Eicosanoids are lipid mediators derived from arachidonic acid, the most studied of which are the prostaglandins and leukotrienes. Although they are primarily known for their roles in asthma, pain, fever and vascular responses, present evidence indicates that eicosanoids exert relevant effects on immune/inflammatory, as well as structural, cells pertinent to fibrogenesis. In general, leukotrienes promote, whereas prostaglandin E2 opposes, fibrogenic responses. An imbalance of eicosanoids also exists in pulmonary fibrosis, which favours the production of leukotrienes over prostaglandin E2. This review highlights the role of this imbalance in the evolution of fibrotic lung disease, discusses the mechanisms by which it may arise and considers approaches for therapeutic targeting of eicosanoids in these conditions.
Skip Nav Destination
Article navigation
June 2005
-
Cover Image
Cover Image
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
Review Article|
May 24 2005
Eicosanoids: mediators and therapeutic targets in fibrotic lung disease
Ryan P. CHARBENEAU;
Ryan P. CHARBENEAU
1Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI 48109-0642, U.S.A.
Search for other works by this author on:
Marc PETERS-GOLDEN
1Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI 48109-0642, U.S.A.
Correspondence: Dr Marc Peters-Golden (email [email protected]).
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
January 12 2005
Revision Received:
February 14 2005
Accepted:
March 17 2005
Online ISSN: 1470-8736
Print ISSN: 0143-5221
The Biochemical Society
2005
Clin Sci (Lond) (2005) 108 (6): 479–491.
Article history
Received:
January 12 2005
Revision Received:
February 14 2005
Accepted:
March 17 2005
Citation
Ryan P. CHARBENEAU, Marc PETERS-GOLDEN; Eicosanoids: mediators and therapeutic targets in fibrotic lung disease. Clin Sci (Lond) 1 June 2005; 108 (6): 479–491. doi: https://doi.org/10.1042/CS20050012
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Biochemical Society Member Sign in
Sign InSign in via your Institution
Sign in via your InstitutionGet Access To This Article
Open Access for all
We offer compliant routes for all authors from 2025. With library support, there will be no author nor reader charges in 5 journals. Check here |
![]() |